Chapter on the development of the W-BQ22


Original development work on the W-BQ


Development of the W-BQ12


http://www.hqlo.com/content/pdf/1477-7525-4-40.pdf


General Commentary

Commentary on FDA draft guidance on patient reported outcome measurement


Recommendation for use of W-BQ in the WHO/IDF St Vincent Declaration Action Programme for Diabetes in Europe


Comparison of standard and computerised versions of the W-BQ


Psychometric Validation of the W-BQ28


Validation of translations of the W-BQ


**Reports of the use of the W-BQ with adults with diabetes**


Reports of use of the W-BQ with other groups

Chronic Illness


Growth Hormone Deficiency


HIV Infection


Macular Disease

Rheumatoid Arthritis


People at high risk of diabetes


CB/19.6.02. Updated 11.3.03/15.4.03/6.5.03/19.8.03/27.11.03/5.8.04/28.9.04 JC/ 5.5.05 CB/1.6.05 JC/ 25.4.06 JB/21.6.06/14.11.06/CB28.11.06/JB17/12/07/ JB5/8/08/ JB20.5.09/ JB9.9.09/ AW18.9.13